FRSW117是一种具有延长半衰期的新型聚乙二醇化重组因子VIII-Fc融合蛋白，单剂量和多剂量FRSW117在严重血友病a患者中的首次人体药代动力学、安全性和初步疗效。

IF 7.9 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2025-06-12 DOI:10.3324/haematol.2024.286964

Feng Xue, Shuxia Guo, Ping Liu, Weizhi Chen, Yun Chen, Qing Wen, Haiying Hua, Yu Cao, Xianqi Feng, Jing Sun, Chongyuan Xu, Renchi Yang

引用次数: 0

摘要

不可用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

First-in-human pharmacokinetic, safety, and preliminary efficacy of single- and multiple-dose FRSW117, a novel PEGylated recombinant factor VIII-Fc fusion protein with an extended half-life, in patients with severe hemophilia A.

Not available.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.